Basic Casodex Information

• INN (International Nonproprietary Name): Bicalutamide
• Brand Names Available In Canada (English): Casodex 50 mg film-coated tablet (AstraZeneca Canada Inc.)
• ATC Code: L02BB03
• Forms & Dosages: Tablet strengths 50 mg and 150 mg; packaging commonly in blisters of 28, 30, 60, 100
• Manufacturers In Canada (English): AstraZeneca Canada Inc.
• Registration Status In Canada (English): Casodex listed as available in Canada; confirm DIN on Health Canada Drug Product Database
• OTC / Rx Classification: Prescription only (Rx)

Latest Research Highlights

Patients ask whether older anti-androgens still matter with newer treatments like enzalutamide and apalutamide on the market.

Recent Canadian and international literature through mid‑2024 continues to recognise bicalutamide as a long‑standing non‑steroidal anti‑androgen with a role in combined androgen blockade for metastatic prostate cancer.

Contemporary studies and meta‑analyses have emphasised sequencing anti‑androgens with next‑generation AR inhibitors and evaluating quality‑of‑life trade‑offs for older agents such as bicalutamide.

Real‑world Canadian registry analyses report ongoing use of bicalutamide in older men and in rural populations where access to injectable LHRH therapy is limited.

• Main Trial Takeaways: bicalutamide retains utility when cost, tolerability or interactions make it preferable.
• Main Trial Takeaways: Sequencing with ARSIs is an active research area.
• Main Trial Takeaways: Real‑world data support continued use in rural and older male cohorts.

• OS: Overall Survival.
• PFS: Progression‑Free Survival.
• ARSI: Androgen Receptor Signalling Inhibitor.

Clinical Effectiveness In Canada

Patients commonly want to know whether casodex will lower PSA and control symptoms.

Clinical effectiveness of bicalutamide in Canada mirrors international experience where it is used as an anti‑androgen added to LHRH agonists for metastatic prostate cancer.

Bicalutamide is also used as higher‑dose monotherapy (150 mg) for selected locally advanced, non‑metastatic cases in some regions.

Canadian observational studies report PSA declines and symptom control consistent with older anti‑androgen outcomes, while survival advantages versus modern AR inhibitors are limited in recent comparative work.

Casodex is marketed in Canada as a 50 mg film‑coated tablet by AstraZeneca Canada Inc.

• Monitoring Measures: Baseline PSA and regular PSA checks.
• Monitoring Measures: Baseline and periodic liver function tests (LFTs) with early monitoring in first months.
• Monitoring Measures: Clinical review for gynecomastia, hot flashes and fatigue.

Indications And Expanded Uses

Many patients ask whether casodex can replace injectable hormone therapy.

Standard indications include use with LHRH analogues at 50 mg once daily for metastatic prostate cancer.

Higher‑dose monotherapy at 150 mg once daily is used for locally advanced, non‑metastatic disease in certain regions.

Off‑label uses in Canadian practice are limited and typically considered by multidisciplinary tumour boards.

Short‑term anti‑androgen therapy to prevent LHRH agonist flare is a common practical use case in clinical care.

• Circumstances For 150 mg Monotherapy: Selected locally advanced non‑metastatic cases under specialist guidance.
• Circumstances For 150 mg Monotherapy: Considered where injectable therapy is unsuitable or declined.
• Circumstances For 150 mg Monotherapy: Provincial approval varies; check formulary rules.

Oral dosing can help adherence in remote communities but requires local capacity for liver‑function monitoring.

Composition And Brand Landscape

Patients frequently ask whether brand or generic casodex is better for them.

The active ingredient is bicalutamide (INN) and the originator brand is Casodex from AstraZeneca.

Globally, strengths include 50 mg and 150 mg tablets with generics produced by Cipla, Intas and others.

• Pros Of Brand: Established supply chain and consistent labelling in English/French.
• Pros Of Generic: Potential cost savings where available.
• Cons Of Generic: Availability in Canada depends on market authorizations and DIN listings.

Canadians expect bilingual labelling and explicit active‑ingredient listing when dispensing or substituting products.

Contraindications And Special Precautions

People worry most about liver effects and whether casodex is safe for older adults.

Absolute contraindications include women, children, hypersensitivity to bicalutamide and severe hepatic impairment.

Relative contraindications include mild‑to‑moderate hepatic disease and concurrent use of warfarin or other narrow therapeutic index drugs.

Liver enzyme elevations are a known risk and liver function must be monitored, especially in the first months of therapy.

• Action Steps For Abnormal LFTs: Repeat tests and assess for other causes.
• Action Steps For Abnormal LFTs: Consider dose interruption or stopping therapy for significant elevations.
• Action Steps For Abnormal LFTs: Report severe hepatotoxicity to prescriber and monitor recovery.

Pharmacists should flag high‑risk interactions and ensure counselling is available in both English and French for Ontario, Quebec and British Columbia patients.

Dosage Guidelines

One of the first questions is “what dose should I take and how often?”.

Typical dosing is 50 mg once daily in combination with an LHRH analogue for metastatic disease.

When used as monotherapy for locally advanced disease, a 150 mg once daily regimen is used in some regions.

No routine dose adjustment is required for elderly patients, but use caution in hepatic impairment.

• Missed Dose: Take as soon as remembered unless next dose is due; do not double up.
• Overdose Response: No specific antidote; provide supportive care and seek medical help.
• Storage Guidance: Store below 25°C and keep in original packaging.

• LHRH: Luteinising Hormone‑Releasing Hormone.
• DIN: Drug Identification Number.
• LFTs: Liver Function Tests.

Interactions Overview

Patients often ask whether casodex will affect blood thinners or cholesterol drugs.

Bicalutamide can interact with drugs metabolised by hepatic enzymes and may alter warfarin anticoagulation control.

International pharmacology data note potential interaction risks with potent CYP inhibitors or inducers, certain statins and some antifungals.

Pharmacists in Canada should check medication records such as PharmaNet in BC or ODB claims before dispensing.

• High‑Risk Drug Classes: Anticoagulants (warfarin), potent CYP inhibitors/inducers, some antidepressants.
• Lifestyle Interactions: Excess alcohol increases hepatic risk and should be minimised.
• OTC And Traditional Remedies: Ask about St. John’s wort and traditional medicines in a respectful, bilingual way.

Cultural Perceptions And Patient Habits

Common patient worries include sexual side effects, gynecomastia and the need for liver tests.

Feedback from Canadian patient groups shows adherence improves with clear, bilingual counselling and easy access to monitoring.

Stigma around prostate cancer and concerns about side effects can reduce help‑seeking in rural or diverse cultural communities.

Pharmacy services that provide bilingual leaflets and telehealth follow‑ups increase adherence and patient confidence.

• Patient Concerns: Cost of medication and uncertainty about coverage.
• Patient Concerns: Frequency of monitoring and travel to clinic for bloodwork.
• Patient Concerns: Clear English/French information on side effects and what to report.

Community outreach and culturally safe communication are important for Indigenous, francophone and remote populations.

Availability And Pricing Patterns

Patients want practical steps to check whether casodex is covered and how much it will cost out of pocket.

Casodex 50 mg film‑coated tablets are available in Canada with packaging commonly dispensed in 28–100 tablets per pack.

Retail prices vary by province and chain and are influenced by provincial formularies such as ODB, PharmaCare and RAMQ.

• Steps To Check Coverage: Look up the DIN on Health Canada’s database and confirm formulary criteria.
• Steps To Check Coverage: Request prior authorization if required by provincial plan.
• Steps To Check Coverage: Verify private insurance policies for oncology drug coverage.

In our online pharmacy, casodex is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Comparable Medicines And Preferences

Patients ask how casodex stacks up against newer drugs like Xtandi (enzalutamide).

Competitors include flutamide, nilutamide and newer AR inhibitors such as enzalutamide and apalutamide.

Comparative studies show newer AR inhibitors may have higher efficacy in some settings but different toxicity and cost profiles.

• Patient‑Facing Pros Of Casodex: Oral dosing, established safety profile, cost considerations.
• Patient‑Facing Cons Of Casodex: Less activity than some ARSIs in selected settings.
• Clinical Preference: Choice guided by stage, comorbidities, interactions and formulary coverage.

Pharmacists should verify DINs for comparators using Health Canada resources at the point of care.

Frequently Asked Questions

Q1: Can I get Casodex in Canada?

A1: Yes, Casodex 50 mg film‑coated tablets are marketed by AstraZeneca Canada Inc.; a prescription is typically required.

Q2: Do provincial plans cover it?

A2: Coverage varies by province and plan; check Ontario Drug Benefit, BC PharmaCare, RAMQ and private insurance; DIN and prior authorization affect access.

Q3: How often are LFTs needed?

A3: Baseline LFTs and early periodic monitoring are recommended; frequency is adjusted per risk and product monograph guidance.

Q4: Can I drive while on bicalutamide?

A4: Most patients can drive, but watch for dizziness or fatigue and consult a pharmacist if symptoms occur.

Q5: Is a generic available in Canada?

A5: Generics are produced internationally (Cipla, Intas) but confirm Canadian market authorizations and DINs before substitution.

• Missed Dose: Take as soon as remembered unless next dose is due; do not double up.
• Overdose Steps: Provide supportive care and seek immediate medical attention.

Guidelines For Proper Use

Patients want clear, checklist‑style guidance before starting casodex.

Prescribe 50 mg daily with an LHRH analogue for metastatic disease and consider 150 mg monotherapy only where regionally approved.

Confirm indication, reconcile concurrent anticoagulant use and arrange baseline LFTs and PSA tests before dispensing.

• Verify Indication: Confirm whether therapy is combination or monotherapy and document treatment intent.
• Confirm Anticoagulation: Check warfarin or other anticoagulants and plan INR monitoring if needed.
• Provide Bilingual Counselling: Supply English and French patient materials and explain side effects and when to seek care.
• Arrange Monitoring: Baseline LFT/PSA, then at 1 month, 3 months and ongoing as clinically indicated.

Use provincial claims systems like PharmaNet or ODB to detect duplicates and to support prior‑authorization requests for reimbursement.

For remote patients, coordinate lab draws with local clinics and use telehealth for symptom checks.

Delivery Across Canada (English)